Click Here to return To Results

 

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis NEJM 358:676-688, Hauser,S.L.,et al, 2008 See this aricle in Pubmed Article Abstract A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of ?-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction B cell lymphocyte depletion B cell lymphocytes gadolinium monoclonal antibodies MRI MRI,abnormal MRI,contrast enhanced MRI,demyelinating disease multiple sclerosis multiple sclerosis,pathogenesis multiple sclerosis,relapsing multiple sclerosis,treatment of rituximab safety treatment of neurologic disorder

Click Here to return To Results